<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128767">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425801</url>
  </required_header>
  <id_info>
    <org_study_id>M/100977/202</org_study_id>
    <nct_id>NCT01425801</nct_id>
  </id_info>
  <brief_title>Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients</brief_title>
  <official_title>A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled
      LAS100977 QD in patients with persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in first second (FEV1)</measure>
    <time_frame>24 hours</time_frame>
    <description>Forced Expiratory Volume in first second (FEV1) will be determined at pre-dose untill 36 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>24 hours</time_frame>
    <description>Forced Vital Capacity (FVC) will be the parameters determined at pre-dose till 36 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events evaluation</measure>
    <time_frame>From Visit 1 to Follow up Visit</time_frame>
    <description>Adverse events: patients will be instructed to spontaneously report any untoward medical occurrence during the clinical trial.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arm #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, double blind treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977</intervention_name>
    <description>Dry powder inhalation,Once daily, single dose</description>
    <arm_group_label>Arm #1</arm_group_label>
    <arm_group_label>Arm #2</arm_group_label>
    <arm_group_label>Arm #3</arm_group_label>
    <arm_group_label>Arm #4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Pressurized inhalation suspension, Once daily , single dose</description>
    <arm_group_label>Arm #5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powder inhalation or Pressurized inhalation</description>
    <arm_group_label>Arm #6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and female patients aged 18-70 years (both included).

          2. Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update)
             for at least 6 months prior to screening.

          3. Screening FEV1 value of 60% &lt; FEV1 ≤ 85% of the predicted normal value.

          4. FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline
             value after inhalation of 400µg (four inhalations) of salbutamol.

          5. Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1
             measured at screening prior to salbutamol inhalation.

          6. Patients on a stable dose and regimen

        Exclusion Criteria:

          1. Current smokers, former smokers within the last 6 months, or ex-smokers with a
             history of more than 10 pack-years.

          2. Patients diagnosed with COPD.

          3. Recent Respiratory tract infections within 6 weeks before Screening Visit.

          4. Intubation (ever) or hospitalization for longer than 24 hours for the management of
             an asthma exacerbation within the preceding 6 weeks of the screening visit.

          5. Clinically significant respiratory conditions.

          6. Clinically significant cardiovascular conditions.

          7. Patients unable to properly use a dry powder or pMDI inhaler device or unable to
             perform acceptable spirometry.

          8. Clinically relevant abnormalities laboratory, ECG parameters or physical examination
             results at the screening evaluation that in the investigator's opinion, preclude
             study participation.

          9. Patients who intend to use any concomitant medication not permitted by this protocol
             or who have not undergone the required washout period for a particular prohibited
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Astbury, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>London</city>
        <zip>W1G 8HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Manchester</city>
        <zip>M3 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>August 29, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
